Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients

doi:10.3748/wjg.v20.i32.11400

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 32

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7829)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

751

WORD

272

HTML

4294

Figures (1-3)

319

Tables (1-3)

256

Sum=5892

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1086

Download

851

Sum=1937

Aug 28, 2014 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (32)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Aug 28, 2014; 20(32): 11400-11405
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11400

Table 3 Summary of the improvement in the urine excretion, ascites and edema after tolvaptan treatment, according to grading criteria, and in the overall improvement n (%)

	n	Significant improvement	Improvement	No improvement
Urine excretion	39	26 (66.7)	9 (23.1)	4 (10.3)
Abdominal circumference	39	19 (48.7)	13 (33.3)	7 (17.9)
Edema (lower extremities)	24	17 (70.8)	5 (20.8)	2 (8.3)
Overall improvement for all patients¹	39	18 (46.2)	17 (43.6)	4 (10.2)
Overall improvement in patients with coexisting hepatocellular carcinoma¹	19	9 (47.4)	7 (36.8)	3 (15.8)
Overall improvement in patients with coexisting hepatorenal syndrome (Type 1)¹	2	0 (0)	0 (0)	2 (100.0)
Overall improvement in patients with coexisting hepatorenal syndrome (Type 2)¹	7	2 (28.6)	5 (71.4)	0 (0)

¹Overall improvement definitions: Significant improvement = grade of A for urine excretion, ascites and edema; Improvement = grade of B for urine excretion and a grade of improvement for ascites or edema; No improvement = grade of C for urine excretion.

Citation: Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405
URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11400.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11400